Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

Original reporting
Published Nov 17, 2026, 1:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ORIC
Bullish
medium confidence
Mentioned
$ORIC
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ORICBullishMed
01

Why it matters

The piece is a catalyst-driven analyst reiteration tied to specific longer-term rinzimetostat progression-free survival estimates and safety, plus a timeline for upcoming Phase 3-related readouts.

02

Market read

Traders get a probability-weighting update for rinzimetostat based on longer-term radiographic progression-free survival durability and a clearer near-term clinical timeline, reinforced by reiterated bullish sell-side stance.

03

What to watch

The article provides follow-up estimates and safety but does not include trial endpoints like overall survival or regulatory milestones, leaving material uncertainty around ultimate clinical and commercial impact.

Relevance 7/10Novelty 6/10Timing: near-term catalyst framing for MEVPRO-1 readout in February 2027

Background

Oric Pharmaceuticals is advancing rinzimetostat in metastatic castration-resistant prostate cancer, with Phase 3 Himalayas-1 enrollment beginning post-abiraterone and a planned MEVPRO-1 readout for mevrometostat.

Company-level read

Ticker impact

$ORICBullishMedium confidence
Context

Wedbush reiterated Outperform and a $14 target after Oric’s Q3 update with longer-term rinzimetostat trial follow-up and Phase 3 enrollment timing.

Expected impact

Likely upward bias as traders price improved durability/safety in rinzimetostat and the upcoming MEVPRO-1 readout.

Evidence & confidence

The article highlights new longer-term radiographic progression-free survival and safety (no Grade 4/5), plus Phase 3 Himalayas-1 enrollment starting and a February 2027 MEVPRO-1 readout, which can shift probability-weighting for the program.

Market effects

Adds incremental read-through for prostate cancer oncology trial expectations and competitive positioning among next-gen castration-resistant prostate cancer therapies.

Limited, primarily impacts US biotech sentiment and small-cap growth risk appetite.

Moderate, as ESMO-related poster activity and multinational trial cohorts can influence global biotech risk pricing.

Counterpoint

Competition from other agents (cited as emerging) could cap upside if efficacy signals do not translate into a clear differentiation versus next-gen rivals.

Key entities

  • Oric Pharmaceuticals

    NASDAQ-listed biotech advancing rinzimetostat; subject of the Wedbush rating reiteration and trial-data update.

  • rinzimetostat

    Oric’s therapy whose longer-term follow-up data are highlighted in post-abiraterone and post-AR inhibitor cohorts.

  • Himalayas-1

    Phase 3 study beginning enrollment in post-abiraterone metastatic castration-resistant prostate cancer.

  • MEVPRO-1

    Upcoming readout for mevrometostat referenced as a near-term indicator for rinzimetostat.

  • JNJ-6143

    Emerging competitive therapy cited by Wedbush as a potential overhang.

Related articles

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo